AZN

AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential

AstraZeneca PLC (AZN) presents a compelling case for investors seeking opportunities within the healthcare sector. With its headquarters in Cambridge, United Kingdom, this biopharmaceutical titan boasts a market capitalization of..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating a Promising 20.91% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, holds a prominent position in the drug manufacturing industry. With a staggering market capitalization of $287.95 billion, this UK-based biopharmaceutical powerhouse..

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free..

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and a 20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a prominent player in the healthcare sector, stands as a titan among global drug manufacturers. With a market capitalization of $290.06 billion, this UK-based biopharmaceutical company..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 23.63% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company headquartered in Cambridge, UK, continues to captivate investor interest with its robust pipeline of prescription medicines and strategic collaborations. As a stalwart in..

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05..

AstraZeneca PLC (AZN): Investor Outlook Reveals 22.39% Upside Potential and Strong Buy Ratings

AstraZeneca PLC (AZN) continues to draw investors’ attention with its robust position in the healthcare sector, specifically within the drug manufacturing industry. Based in the United Kingdom, the company is..

AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 21% Potential Upside Opportunity

AstraZeneca PLC (AZN), a leading player in the biopharmaceutical sector, continues to capture investor attention with its robust market presence and a significant potential upside. This UK-based healthcare giant, with..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 11.51% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company based in the United Kingdom, remains a compelling choice for investors seeking exposure to the healthcare sector. With a market capitalization of $294.17..

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...

AstraZeneca PLC (AZN) Stock Analysis: Eyeing Modest Upside Amid Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector and a prominent player among general drug manufacturers, continues to garner significant investor interest. With a market capitalization of $317.5..

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth and a Strategic Edge in Healthcare

AstraZeneca PLC (NASDAQ: AZN), a leading entity in the healthcare sector, is making waves with its robust market position and strategic advancements in the biopharmaceutical industry. Currently boasting a market..

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth with a $315 Billion Market Cap and Promising Analyst Ratings

AstraZeneca PLC (AZN), a key player in the global healthcare sector, continues to capture investor attention with its robust market presence and expansive pharmaceutical portfolio. With a market capitalization of..

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim..

AstraZeneca PLC (AZN) Stock Analysis: Navigating Potential 10.68% Upside Amid Strategic Growth

AstraZeneca PLC (AZN), a leading player in the global healthcare sector, presents an intriguing investment opportunity for those looking to navigate the dynamic world of pharmaceuticals. With a robust market..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating Growth Potential Amid a 13.53% Upside

AstraZeneca PLC (NASDAQ: AZN), a leading player in the healthcare sector, is drawing investor attention with a market capitalization of $284.63 billion and a strong presence in the biopharmaceutical landscape...

AstraZeneca PLC (AZN) Stock Analysis: Navigating a 1.86% Potential Upside Amidst Strong Analyst Ratings

AstraZeneca PLC (NYSE: AZN), a global leader in the biopharmaceutical realm, continues to capture investor attention with its robust portfolio and promising financial outlook. With a current market capitalization of..

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN..
Search

Funds

AZN

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival...

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials...

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN trial data demonstrating reduced risk of progression and death...
Search

Funds

AZN

FTSE 100

Funds